Armata Pharmaceuticals Elects Board Members at Annual Meeting

Armata Pharmaceuticals ( (ARMP) ) has issued an announcement.

At the Annual Meeting of Shareholders on June 12, 2025, Armata Pharmaceuticals elected seven board members for a one-year term ending in 2026. Shareholders also approved the compensation of the company’s executive officers and ratified Ernst & Young LLP as the independent accounting firm for the fiscal year ending December 31, 2025.

The most recent analyst rating on (ARMP) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Armata Pharmaceuticals stock, see the ARMP Stock Forecast page.

Spark’s Take on ARMP Stock

According to Spark, TipRanks’ AI Analyst, ARMP is a Neutral.

Armata Pharmaceuticals’ overall score is primarily impacted by its financial distress, with persistent losses and negative equity. However, recent positive trial results and strategic financing provide a potential turning point, with technical indicators showing some short-term bullish momentum.

To see Spark’s full report on ARMP stock, click here.

More about Armata Pharmaceuticals

Armata Pharmaceuticals, Inc. operates in the pharmaceutical industry, focusing on the development of bacteriophage-based therapies to treat antibiotic-resistant infections.

Average Trading Volume: 247,050

Technical Sentiment Signal: Sell

Current Market Cap: $73.47M

For a thorough assessment of ARMP stock, go to TipRanks’ Stock Analysis page.